Status:
COMPLETED
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
Lead Sponsor:
National Institute of Cardiovascular Diseases, Pakistan
Conditions:
Acute Coronary Syndrome
No-Reflow Phenomenon
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
No-reflow is defined as the lack of myocardial perfusion despite opening of the epicardial coronary vessels in the setting of percutaneous coronary intervention (PCI). It has been demonstrated that ei...
Eligibility Criteria
Inclusion
- All patients with acute coronary syndrome who developed No-reflow during PCI.
- Patients with systolic blood pressure of \> 100 mmHg.
Exclusion
- Hypotensive patients
- Patients with Valvular or congenital heart disease.
- Patients with Atypical chest pain
- Patients with Cardiomyopathy
- Patients with Pericarditis
- Patients with Myocarditis
- Patients refused to give consent
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
201 Patients enrolled
Trial Details
Trial ID
NCT04699110
Start Date
January 1 2021
End Date
April 30 2021
Last Update
May 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of Cardiovascular Diseases
Karachi, Sindh, Pakistan